CLOs on the Move

Nebraska Methodist Health System

www.bestcare.org

 
Methodist Health System, 3 hospitals, 21 clinic locations, a nursing and allied health college, in Omaha, NE
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.bestcare.org
  • 8511, West Dodge Road
    Omaha, NE USA 68114
  • Phone: 402.354.4858

Executives

Name Title Contact Details

Similar Companies

Whip Mix Corp.

Whip Mix is the one resource that helps the Dental Profession achieve its goals of high quality, less invasive patient care, reduced chair time and increased operating efficiencies.

Gravie

Gravie has been at the forefront of driving change and improving the healthcare industry by creating innovative employer-sponsored health benefit solutions that put consumers first. Comfort™, Gravie`s flagship product, is the nation`s first-of-its-kind health plan that provides zero-deductible, zero-copay, and 100% coverage on most common healthcare services, at a cost comparable to most traditional group health plans.

WelbeHealth

WelbeHealth is a company that provides full service healthcare and personalized support to help seniors age well at home and in their community.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.